Published in Transl Lung Cancer Res on April 01, 2017
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med (2015) 12.54
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med (2015) 11.98
Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med (2012) 8.46
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature (2015) 7.49
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med (2016) 6.84
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol (2012) 5.32
Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys (2004) 4.29
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet (2016) 4.12
Systemic effects of local radiotherapy. Lancet Oncol (2009) 2.97
Low-dose irradiation programs macrophage differentiation to an iNOS⁺/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell (2013) 2.89
Whole body irradiation; radiobiology or medicine? Br J Radiol (1953) 2.80
Second-line or subsequent systemic therapy for recurrent or progressive non-small cell lung cancer: a systematic review and practice guideline. J Thorac Oncol (2006) 2.66
Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J Immunol (2003) 2.51
Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Cancer Res (2002) 2.35
Radiation pneumonitis and fibrosis: mechanisms underlying its pathogenesis and implications for future research. Int J Radiat Oncol Biol Phys (2006) 2.34
Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys (2013) 2.28
Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. J Neurosurg (2012) 2.28
Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2008) 2.22
Post-recurrence survival in completely resected stage I non-small cell lung cancer with local recurrence. Thorax (2009) 1.97
Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. Clin Cancer Res (2007) 1.86
Flt3-ligand administration after radiation therapy prolongs survival in a murine model of metastatic lung cancer. Cancer Res (1999) 1.60
Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res (2014) 1.52
Radiation and immunotherapy: a synergistic combination. J Clin Invest (2013) 1.44
High-dose, conventionally fractionated thoracic reirradiation for lung tumors. Lung Cancer (2013) 1.40
Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial. Melanoma Res (2011) 1.35
Definitive chemoradiation for the treatment of locally advanced non small-cell lung cancer. J Clin Oncol (2007) 1.31
Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol (2016) 1.23
Reirradiation for locally recurrent lung cancer previously treated with radiation therapy. Int J Radiat Oncol Biol Phys (2002) 1.20
Ipilimumab and radiation therapy for melanoma brain metastases. Cancer Med (2013) 1.15
Radiation necrosis of the brain in melanoma patients successfully treated with ipilimumab, three case studies. Eur J Cancer (2012) 1.13
Three-dimensional conformal radiotherapy for locoregionally recurrent lung carcinoma after external beam irradiation: a prospective phase I-II clinical trial. Int J Radiat Oncol Biol Phys (2003) 1.09
Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases. J Neurooncol (2014) 1.09
Toxicity after reirradiation of pulmonary tumours with stereotactic body radiotherapy. Radiother Oncol (2011) 1.08
Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery. Melanoma Res (2013) 1.08
Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. J Clin Oncol (2016) 1.06
The reirradiation of recurrent bronchogenic carcinoma with external beam irradiation. Am J Clin Oncol (1993) 1.04
Symptomatic Histologically Proven Necrosis of Brain following Stereotactic Radiation and Ipilimumab in Six Lesions in Four Melanoma Patients. Case Rep Oncol Med (2014) 0.99
Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer (2016) 0.96
Ipilimumab with stereotactic ablative radiation therapy: Phase I results and immunologic correlates from peripheral T-cells. Clin Cancer Res (2016) 0.96
Toxicity and outcomes of thoracic re-irradiation using stereotactic body radiation therapy (SBRT). Radiat Oncol (2013) 0.95
Two heads better than one? Ipilimumab immunotherapy and radiation therapy for melanoma brain metastases. Neuro Oncol (2015) 0.92
Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model. Cancer Immunol Res (2015) 0.90
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol (2016) 0.90
Definitive reirradiation for locoregionally recurrent non-small cell lung cancer with proton beam therapy or intensity modulated radiation therapy: predictors of high-grade toxicity and survival outcomes. Int J Radiat Oncol Biol Phys (2014) 0.87
Treatment of recurrent disease in lung cancer. Semin Surg Oncol (2003) 0.86
Palliative retreatment of locally-recurrent lung cancer after radical radiotherapy. Med J Aust (1987) 0.84
Systemic Immunotherapy for the Treatment of Brain Metastases. Front Oncol (2016) 0.82
Safety and palliative efficacy of single-dose 8-Gy reirradiation for painful local failure in patients with stage IV non-small cell lung cancer previously treated with radical chemoradiation therapy. Int J Radiat Oncol Biol Phys (2015) 0.81
Advances in cytotoxic chemotherapy for the treatment of metastatic or recurrent non-small cell lung cancer. Semin Oncol (2005) 0.79
Stereotactic body radiotherapy for re-irradiation of lung cancer recurrence with lower biological effective doses. J Radiat Oncol (2014) 0.76
Multi-institutional Prospective Study of Reirradiation with Proton Beam Radiotherapy for Locoregionally Recurrent Non-Small Cell Lung Cancer. J Thorac Oncol (2016) 0.76
Re-irradiation for locoregionally recurrent tumors of the thorax: a single-institution, retrospective study. Radiat Oncol (2016) 0.75
Impact of heart and lung dose on early survival in patients with non-small cell lung cancer treated with chemoradiation. Radiother Oncol (2016) 0.87
Cardiac atlas development and validation for automatic segmentation of cardiac substructures. Radiother Oncol (2016) 0.75